Helical tomotherapy in the radiotherapy treatment of Hodgkin's disease - a feasibility study

被引:3
|
作者
Vlachaki, Maria T. [1 ]
Kumar, Sanath [2 ]
机构
[1] British Columbia Canc Agcy, Vancouver Isl Ctr, Dept Radiat Oncol, Victoria, BC V8R 6V5, Canada
[2] Henry Ford Hosp, Dept Radiat Oncol, Detroit, MI 48202 USA
来源
关键词
3D CRT; Helical TomoTherapy; Hodgkin's Disease; INVOLVED-FIELD RADIOTHERAPY; GUIDED TOTAL-MARROW; RADIATION-THERAPY; ORGAN MOTION; RISK-FACTORS; CANCER-RISK; LYMPHOMA; IRRADIATION; CHILDREN; CHEMOTHERAPY;
D O I
10.1120/jacmp.v11i1.3042
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Radiation therapy for advanced Hodgkin's disease often requires large fields and may result in significant exposure of normal tissues to ionizing radiation. In longterm survivors, this may increase the risk for late toxicity including secondary malignancies. 3D CRT has been successfully used to treat this disease but treatment delivery is often complex requiring matching of photon with electron beams, and utilization of field-in-field techniques and of partial transmission blocks. HT is an arc-rotational intensity modulated radiation therapy technique proven to achieve superior target dose conformality and sharp dose gradients around critical normal tissues. HT, however, has also been associated with higher volumes of low-dose regions in normal tissues and, therefore, higher integral dose. The present study was undertaken to compare the dosimetry of 3D CRT to HT in a pediatric patient with advanced HD. Clinical target volume (CTV) included bilateral lower cervical and supraclavicular areas, mediastinum, bilateral hili, left axilla and bilateral diaphragmatic lymph nodes. The planning target volume (PTV) was derived by circumferentially expanding the CTV by 1 cm. Whole lung and heart irradiation was also planned due to bilateral pleural and pericardial effusions. The prescribed radiation dose was 21 Gy to the PTV and 10.5 Gy to the whole lung and heart. Target coverage was comparable for both plans. The minimum, maximum, and mean PTV doses were 18.61 Gy, 22.45 Gy and 21.52 Gy with 3D CRT and 19.85 Gy, 22.36 Gy and 21.39 Gy with HT, respectively. HT decreased mean normal tissue dose by 21.6% and 20.07% for right and left breast, 20.40% for lung, 30.78% for heart, and 22.74% for the thyroid gland. Integral dose also decreased with HT by 46.50%. HT results in significant dosimetric gain related to normal tissue sparing compared to 3D CRT. Further studies are warranted to evaluate clinical applications of HT in patients with HD.
引用
收藏
页码:77 / 87
页数:11
相关论文
共 50 条
  • [31] TREATMENT PLANNING FOR PULSED REDUCED DOSE-RATE RADIOTHERAPY IN HELICAL TOMOTHERAPY
    Rong, Yi
    Paliwal, Bhudatt
    Howard, Steven P.
    Welsh, James
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (03): : 934 - 942
  • [32] Evaluation of Pulmonary Function After Radiotherapy Using Helical Tomotherapy for Breast Cancer Treatment: Prospective Study
    Teke, Fatma
    Demir, Melike
    Erten Bucaktepe, Pakize Gamze
    Kaya, Mehmet Ali
    Dogan, Mehmet Hakan
    Kucukoner, Mehmet
    Zincircioglu, Seyit Burhanedtin
    Teke, Memik
    [J]. TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2016, 31 (03): : 89 - 96
  • [33] Helical tomotherapy in the treatment of pediatric malignancies: a preliminary report of feasibility and acute toxicity
    Latifa Mesbah
    Raúl Matute
    Sergey Usychkin
    Immacolata Marrone
    Fernando Puebla
    Cristina Mínguez
    Rafael García
    Graciela García
    César Beltrán
    Hugo Marsiglia
    [J]. Radiation Oncology, 6
  • [34] Helical Tomotherapy with daily image guided radiotherapy for neoadjuvant treatment of rectal cancer
    De Bari, B.
    Pellanda, A. Franzetti
    Saidi, A.
    Ballerini, G.
    Biggiogero, M.
    Negretti, L.
    Durham, A.
    Bourhis, J.
    Ozsahin, M.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S613 - S613
  • [35] Radiotherapy for women with stage II supradia-phragmatic Hodgkin's disease: a dosimetric comparison of IMRT by Helical TomoTherapy and a 3D-conformal radiotherapy (3D-CRT)
    Antoni, D.
    Meyer, P.
    Ame, S.
    Niederst, C.
    Bourahla, K.
    Guillerme, F.
    Noel, G.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 (10) : 685 - 685
  • [36] Multitarget radiotherapy of primary disseminated multifocal Ewing's sarcoma with Helical Tomotherapy
    Krause, S.
    Klueter, S.
    Neuhof, D.
    Oetzel, D.
    Herfarth, K.
    Debus, J.
    Sterzing, F.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 (10) : 678 - 679
  • [37] A feasibility study of stereotactic radiosurgery/stereotactic body radiotherapy/stereotactic ablative radiotherapy practice using tomoedge in helical tomotherapy for lung, liver, and spine targets
    Sresty, N. V. N. Madhusudhana
    Raju, A. Krishnam
    Kumar, G. Deleep
    Rohit, S.
    Reddy, B. Nagarjuna
    Sahithya, V. C.
    Reddy, B. Devender
    Mohd, Yakub
    Rushdi, Tasneem
    Bajwa, Harjoth
    Aparna, S.
    [J]. JOURNAL OF MEDICAL PHYSICS, 2021, 46 (03) : 204 - 210
  • [38] Dosimetric comparison of active scanning Proton Therapy and Helical Tomotherapy in pediatric and adolescent Hodgkin's lymphoma treated with tomotherapy
    Righetto, Chairs R.
    Drigo, A.
    Rombi, B.
    Coassin, E.
    Dionisi, F.
    Pirrone, G.
    Burnelli, R.
    Schwarz, M.
    Sartor, G.
    Amichetti, M.
    Mascarin, M.
    [J]. KLINISCHE PADIATRIE, 2020, 232 (02): : 108 - 108
  • [39] Radiotherapy for Hodgkin's disease.
    Kocher, M
    Staar, S
    Muller, RP
    [J]. TUMORDIAGNOSTIK & THERAPIE, 1996, 17 (05) : 158 - 160
  • [40] Radiotherapy for Hodgkin's disease and lymphosarcoma
    Desjardins, AU
    [J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1932, 99 : 1231 - 1236